🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guadalajara
Clinical trial register · Mexico

Clinical Trials in Guadalajara, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Mexico and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1580 matching records held by the registry are in this view. Synced 30 Sep 2026, 03:17 UTC
1580
Studies in scope
all four open statuses
714
Recruiting now
open to new participants
249
Lead sponsors
across recruiting studies
Top sites
Mexico City 48 Monterrey 42 Oaxaca City 33 Guadalajara 30 Chihuahua City 15
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company40 AstraZeneca35 Merck Sharp & Dohme LLC30 Hoffmann-La Roche24 Bristol-Myers Squibb18 Clear sponsor filter
Site location
Mexico City48 Monterrey42 Oaxaca City33 Guadalajara30 Chihuahua City15
All 41 locations
Target enrolment
to

Trials with a site in Guadalajara

30 of 1580 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Mexico
Start
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703Cervical Cancer
DrugsMvasi·Paraplatin·Avastin·Taxol
Merck Sharp & Dohme LLC
Phase 3
1,023
Guadalajara, Benito Juárez, Mexico City, Monterrey, Chihuahua City, Oaxaca City
2026-01-19
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402Renal Cell Carcinoma
DrugsZanzalintinib·Belzutifan·Cabozantinib
Merck Sharp & Dohme LLC
Phase 3
904
Guadalajara, Monterrey, Oaxaca City, Mexico City, Puebla City
2025-11-26
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248Non-small Cell Lung Cancer
Drugs) Berahyaluronidase alfa·Calderasib·Paraplatin·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
675
Guadalajara, Benito Juárez, Monterrey, Oaxaca City, Chihuahua City, Mexico City, Puebla City
2025-10-08
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807Breast Neoplasms
DrugsLiposomal doxorubicin·Patritumab deruxtecan·Xeloda·Abraxane
Merck Sharp & Dohme LLC
Phase 3
1,000
Guadalajara, Monterrey, Querétaro City, Chihuahua City, Oaxaca City
2025-07-21
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma
DrugsBevacizumab biosimilar·Calderasib·Adrucil·Cetuximab
Merck Sharp & Dohme LLC
Phase 3
477
Guadalajara, Mexico City, Monterrey, San Pedro Garza García, Aguascalientes, Oaxaca City
2025-07-16
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,123
Guadalajara, Monterrey, Oaxaca City, Aguascalientes, Chihuahua City
2025-05-22
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Pachuca, Guadalajara, Mexico City, Monterrey, Oaxaca City
2025-05-13
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Avastin
Merck Sharp & Dohme LLC
Phase 3
770
Guadalajara, Mexico City, Monterrey, Aguascalientes, Cuauhtémoc, Oaxaca City
2025-04-09
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
DrugsAbraxane·Paraplatin·Taxol·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
1,000
Guadalajara, Benito Juárez, Mexico City, Monterrey, San Pedro Garza García, Oaxaca City, Aguascalientes, Chihuahua City
2025-03-16
Active, closed
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291Hypercholesterolemia
DrugsEnlicitide·Enlicitide Decanoate
Merck Sharp & Dohme LLC
Phase 3
3,000
Guadalajara, Mexico City
2024-08-05
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754Non-small Cell Lung Cancer (NSCLC)
DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
550
Guadalajara, Mexico City, Monterrey, Oaxaca City
2024-06-11
Active, closed
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311Gastroesophageal Cancer
DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
450
Guadalajara, Mexico City, Monterrey, Oaxaca City, San Luis Potosí City
2024-05-03
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176Breast Neoplasms
DrugsLiposomal doxorubicin·Xeloda·Abraxane·Taxol
Merck Sharp & Dohme LLC
Phase 3
1,200
Guadalajara, Mexico City, Monterrey, San Pedro Garza García
2024-04-14
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
780
Guadalajara, Monterrey, Oaxaca City, Chihuahua City
2024-04-03
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,310
Guadalajara, Mexico City, Monterrey, Mérida
2023-12-31
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,314
Guadalajara, Mexico City, Tlalpan, Monterrey
2023-12-18
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Guadalajara, Mexico City, Monterrey, San Luis Potosí City, Oaxaca City, Puebla City
2023-12-15
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
868
Pachuca, Guadalajara, Mexico City, Monterrey, Chihuahua City, Distrito Federal, Oaxaca City
2023-12-06
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
556
Guadalajara, Monterrey, Oaxaca City, Puebla City
2023-11-12
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,109
León, Guadalajara, Tlajumulco de Zuniga, Mexico City, Monterrey, Mérida, Chihuahua City, Oaxaca City
2023-10-25
Active, closed
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756Arteriosclerosis, Hypercholesterolaemia
DrugEnlicitide Decanoate
Merck Sharp & Dohme LLC
Phase 3
14,550
Tijuana, León, Pachuca, Guadalajara, Zapopan, Gustavo Adolfo Madero, Mexico City, General Escobedo
2023-10-09
Recruiting
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction
DrugVericiguat
Merck Sharp & Dohme LLC
Phase 2/3
342
León, Guadalajara, Mexico City, Monterrey, Hacienda de Las Palmas, Ciudad Madero, Aguascalientes, Colima
2023-05-31
Active, closed
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141Small Cell Lung Carcinoma
DrugsPembrolizumab/Vibostolimab·Paraplatin·Tecentriq·Etoposide
Merck Sharp & Dohme LLC
Phase 3
460
Guadalajara, Mexico City, Monterrey, Oaxaca City
2022-03-24
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
DrugsBelzutifan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,800
Guadalajara, Mexico City, Monterrey, Querétaro City, Culiacán, Oaxaca City, Puebla City
2022-03-15
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
DrugsLiposomal doxorubicin·Xeloda·Abraxane·Taxol
Merck Sharp & Dohme LLC
Phase 3
342
Guadalajara, Mexico City, Monterrey, Chihuahua City, Oaxaca City
2021-06-18
Active, closed
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04736706Carcinoma, Renal Cell
DrugsPembrolizumab/Quavonlimab·Belzutifan·Lenvatinib·Keytruda
Merck Sharp & Dohme LLC
Phase 3
1,854
Guadalajara, Mexico City, Monterrey, Querétaro City, Oaxaca City
2021-04-14
Active, closed
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204Small Cell Lung Cancer
DrugsOlaparib·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
672
Guadalajara, Monterrey
2020-12-08
Active, closed
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04380636Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsParaplatin·Taxol·Olaparib·Etoposide
Merck Sharp & Dohme LLC
Phase 3
870
Guadalajara, Monterrey, Orizaba, Tlalpan
2020-07-06
Active, closed
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
NCT03742895Advanced Solid Neoplasms
DrugOlaparib
Merck Sharp & Dohme LLC
Phase 2
329
Guadalajara, Monterrey, Santiago de Quetaro, Madero, Chihuahua City, Mexico City, México, Oaxaca City
2018-12-12
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib
Merck Sharp & Dohme LLC
Phase 3
3,500
La Paz, Guadalajara, Mexico City, Monterrey, San Pedro Garza García, Oaxaca City, Ciudad Madero, Mérida
2018-08-21
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Mexican investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-mexico/city/guadalajara

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Mexico and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,580 studies in total at the last sync on 30 Sep 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies with a site in Guadalajara that also match the filters currently applied.

How many clinical trials are recruiting in Guadalajara?

16 of the 30 studies on this page are recruiting new participants as of the 30 Sep 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 14 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guadalajara), 30 studies
PhaseStudiesRecruitingShare
Phase 3281593.3%
Phase 2103.3%
Phase 2/3113.3%

Most active sponsors

Lead sponsors with the most studies (Guadalajara)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC3016
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.